The integrin alpha 4 beta 1 (VLA-4) as a therapeutic target.
Disease models in animals demonstrate that the leukocyte integrin alpha 4 beta 1 (VLA-4) is a suitable target for therapy in a number of chronic inflammatory disorders. While in vivo studies have concentrated on the use of anti-alpha 4 antibodies as proof of concept tools, repeated administration to combat human chronic inflammatory conditions is likely to require small antagonists of alpha 4 beta 1. We have developed low molecular weight alpha 4 beta 1 inhibitors which have shown therapeutic promise in animal models of chronic inflammation.
Elices
M J
MJ
Cytel Corporation, San Diego, CA 92121, USA.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism; D039041:Integrin alpha4beta1; D016023:Integrins / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D016201:Receptors, Lymphocyte Homing / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism
D000911:Antibodies, Monoclonal; D039041:Integrin alpha4beta1; D016023:Integrins; D016201:Receptors, Lymphocyte Homing